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Summary 
In tropical and developing countries, arboviruses cause emerging and reemerging infectious diseases. The 
East African region has experienced several outbreaks of Rift valley fever virus, Dengue virus, 
Chikungunya virus and Yellow fever virus. In Kenya, data from serological studies and mosquito isolation 
studies have shown a wide distribution of arboviruses throughout the country, implying the potential risk 
of these viruses to local public health. However, current estimates on circulating arboviruses in the country 
are largely underestimated due to lack of continuous and reliable countrywide surveillance and reporting 
systems on arboviruses and disease vectors and the lack of proper clinical screening methods and modern 
facilities. In this review, we discuss arboviruses of human health importance in Kenya by outlining the 
arboviruses that have caused outbreaks in the country, alongside those that have only been detected from 
various serological studies performed. Based on our analysis, at the end we provide workable technical and 
policy-wise recommendations for management of arboviruses and arboviral vectors in Kenya.  
[Afr J Health Sci. 2018; 31(1):121-141] 
Introduction 
Arthropod-borne viruses (Arboviruses) are a cause 
of significant human and animal diseases worldwide. 
In history, Dengue virus, Yellow fever virus, 
Japanese encephalitis virus have caused notable 
epidemics, leading to human and animal morbidity 
and mortality. Recently, the outbreak of Zika virus 
became a global public security event, due to its 
ability to cause congenital brain abnormalities, 
including microcephaly and in some cases, being a 
trigger of Guillain-Barré syndrome. The control of 
arboviruses is rapidly becoming a priority in national 
and global public health systems. 
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Mosquitoes, ticks, sand flies, and midges are the 
main vectors responsible transmission of these 
diseases. For a variety of these viruses, the vector has 
been alleged to be an important reservoir during non-
epidemic cases [1]. The currently known mosquito-
borne infections include viruses from the families 
Peribunyaviridae (Rift Valley Fever Virus), 
Flaviviridae (Dengue virus, Yellow Fever Virus, 
West Nile Virus, Japanese Encephalitis virus, Zika 
virus), Togaviridae (Chikungunya virus, O’nyong-
nyong virus, Sindbis virus, Semiliki Forest Virus) 
[2], [3]. Ticks have been evidenced to transmit 
viruses from the families Nairoviridae (Crimean 
Congo Hemorrhagic Fever virus), Togaviridae 
(Eastern Equine Encephalitis virus, Venezuelan 
Equine Encephalitis virus, Western Equine 
Encephalitis virus) and Flaviviridae (Tick Borne 
Encephalitis virus), while midges such as culicoides 
have been reported to transmit livestock viruses such 
as African Swine Fever virus and Bluetongue virus 
[4], [5].  
Despite the presence of known competent arboviral 
vectors, together with the emergence and thriving of 
arboviral diseases [6], the potential risk of the 
arboviruses to the public health in Kenya is greatly 
underestimated owing to a lack of reliable 
monitoring and reporting system, proper clinical 
screening methods and facilities, continuous 
countrywide surveillance of viruses and vectors [7]. 
Several cases of disease are reported and 
documented during the outbreak episodes and little 
or no investigations are carried out in the inter-
epidemic periods. Furthermore, the public hospitals 
are quite limited in the diagnostic resources leading 
to several cases of misdiagnosis based on clinical 
presentation of diseases. This has inadvertently led 
to unreliable statistics on the prevalence of arboviral 
diseases in Kenya. While most disease 
documentation is limited to the outbreak episodes, 
serological studies conducted over the past decade 
have revealed an ongoing circulation of arboviruses 
at low- levels during the inter-epidemic seasons. This 
low- level circulation if monitored can provide a 
guiding avenue for control of diseases which later 
explode into outbreaks when the factors are suitable.  
The viruses that have been shown to occur in low-
level circulation include Dengue virus, Chikungunya 
virus, Yellow Fever virus, West Nile Virus, Tick-
borne encephalitis virus [8], O’Nyong Nyong virus 
[9] and Rift valley fever virus [2]. In the past, notable 
outbreaks caused by these viruses have occurred and 
some have resulted in severe disease and even deaths.  
In this review, we take a journey through the 
outbreaks and serological surveillance efforts, with 
regard to Arboviruses in Kenya. The data used in this 
report was obtained from publicly available disease 
and outbreak information from various platforms 
such as published articles, Kenyan government 
 123 
African Journal of Health Sciences, Volume 31, Number 1, January-March 2018 
 
online resources and WHO online records, for the 
years 1912- 2017. We present a map of the existing 
knowledge and gaps in the concerted effort to combat 
arboviral infections in Kenya. In this, we categorize 
these arboviral infections into three groups; (1) 
Arboviruses that have caused an outbreak in Kenya, 
(2) Arboviruses that have only been detected through 
serological evidence and (3) Other insect-associated 
arboviruses that are in low circulation. 
Reported Arbovirus outbreaks 
In the past, several arbovirus disease outbreaks have 
occurred in Kenya (Fig. 2). In this section, we discuss 
the documented arboviruses outbreaks that have had 
a great public health and socio-economic impact in 
the country. 
Dengue virus (Flaviviridae) 
Dengue virus (DENV) was first detected in 1943 in 
Japan and later in 1945 in Hawaii [10]. It is a 
flavivirus within the family flaviviridae and has been 
classified into four different serotypes; DENV I, 
DENV II, DENV III and DENV IV). In 2013 a fifth 
serotype was  detected and designated DENV V [11]. 
Aedes species which are drawn to human blood and 
feed in the daytime are the primary vectors of DENV 
with Aedes aegypti being the most important. DENV 
has been considered the most important arbovirus 
owing to its distribution and the characteristically 
severe disease [12]. The virus causes a febrile illness 
which can range from a simple febrile illness, to a 
more severe Dengue Hemorrhagic fever which can 
progress to a fatal form, Dengue Shock Syndrome 
(DSS). In 2015 recombinant tetravalent live vaccine, 
Dengvaxia (CYD-TDV) was licensed and first 
applied in Mexico. Despite variable efficacy in the 
four DENV serotypes [13], this vaccine is now 
commercially available in several Asian and Latin 
American countries while others are in the clinical 
phase. Studies have shown that infection with one 
serotype of dengue provides a lifelong homotypic 
protection and may provide a short-term cross-
protection against other serotypes [14]. However, 
secondary infections carry the potential of being very 
severe and advancing to DHF/DSS [13] a mechanism 
that is not very well understood. 
In Kenya, the first recorded case of Dengue outbreak 
occurred in 1982 when an outbreak of febrile illness 
occurred in Malindi at the coastal region of Kenya 
(15). This outbreak was caused by the DENV-2 
serotype and spread quickly to nearing towns of 
Mombasa and Diani.  Several years later in 2011, a 
second outbreak was reported in Kenya in the 
Northern part of the country, Mandera. In the years 
preceding this outbreak, Dengue fever continued to 
occur in other African countries [16]. A serological 
and virological analysis of arboviruses circulating in 
Kenya done in 2011 showed presence of the four 
DENV serotypes in the Coastal population as well as 
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inland but did not capture the Northeastern region 
where the outbreak later occurred [8]. The 2011- 
2014 outbreak occurred in Northeastern Kenya as 
well as Mombasa in the coastal area of the country 
and was shown to be caused by DENV1-3 serotypes 
[17]. This outbreak was larger in geographical range 
as well as number of infections. Recently, another 
outbreak occurred in Kenya in May 2017 and it 
affected 6 sub-counties in the coast region (The 
Standard Newspaper, May 2017). This region 
experiences a significant traffic of tourists as well as 
business personnel due to the existing trading port. It 
provides a hotspot for potential exportation of the 
virus bearing in mind the incubation period of 
dengue is 1-7 days to onset of fever. Serological 
studies carried out in this region have shown a 
continuous low-level circulation of DENV during 
non-epidemic periods and small sporadic outbreaks 
that may go unreported.  
Rift Valley Fever Virus (Peribunyaviridae) 
RVFV was first identified in the early 1930s in the 
Rift valley region, Kenya [18]. Previous records have 
shown a disease with similar characteristics to the 
RVFV-disease spreading among sheep, lambs and 
cattle causing high mortalities and abortions [19], 
[20]. An outbreak in a farm in Naivasha that resulted 
in the deaths of over 100 sheep led to the 
identification of RVF as the causative agent of the 
disease [21] The virus causes both human and 
livestock disease. Humans contract the virus either 
from bites from infected mosquitoes or having 
contact with blood or organs from infected animals. 
To date, no human-to-human transmission case has 
been documented.  RVFV infection in humans leads 
to a self-limiting, acute febrile illness. Although a 
small set of cases do progress to neurological 
disorders, partial or complete blindness, hemorrhagic 
fever, or thrombosis. Its incubation period ranges 
from 2-6 days [22], [23]. There is no available safe 
and effective RVFV vaccine that can protect humans 
against the great side effects of this virus [24]. 
However, one vaccine has been applied 
experimentally in protection of highly exposed 
personnel like veterinarians and laboratory workers 
to RVFV [25]. There is however an inactivated 
vaccine used in animals [26], [27] and it is perceived 
as a limiting factor for the amplification of the virus 
and hence reduction of spread and hence 
transmission to humans.  
Aedes spp. mosquitoes, such as Ae. mcintoshi or Ae. 
vexans, are the main vectors, and it has been 
determined that the virus can be transmitted into the 
offspring transovarially [24], [28]. In known 
endemic regions, heavy rains and floods increase 
fresh water species of mosquitoes such as Culex 
pipens, which have a key role in RVFV amplification 
among mosquitoes, animals and humans [29], [30]  
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RVFV spread and transmission in RVFV-free 
countries is aided by presence of competent 
mosquito vectors coupled with global climatic 
changes, high viraemic titres in viraemic animals, 
travel and trade; posing a very huge global health 
threat. The disease is now known to be endemic in 
sub-Saharan Africa owing to its subsequent spread 
and resulting epidemics in the region. Major RVFV 
epidemics have been recorded in several countries 
including Kenya, Tanzania, Sudan, Somalia, South 
Africa, Madagascar, Mauritania, Egypt, Senegal, 
Saudi Arabia and Yemen (22).  
In December 1997-1998, RVF outbreak occurred in 
Garissa District, North Eastern province of Kenya. 
170 hemorrhagic deaths were reported. A serological 
study conducted in the region showed a 14% as the 
prevalence rate and it further estimated that 27,500 
human infections occurred during the period hence 
making it the largest ever recorded RVFV outbreak 
to have occurred in sub-Sahara Africa by then [31] 
To date, the most significant and extensive RVF 
outbreak in Kenya occurred in 2006-2007. 
Thousands of epizootic cases were reported in cattle, 
sheep, goats, and camels from 29 of 69 
administrative districts across six of the eight 
provinces. 684 human RVF cases including 243 
deaths from RVF were reported (WHO); with 
approximately 85% of these cases experienced in 
four districts namely; Garissa and Ijara districts in 
Northeastern Province, Baringo district in Rift 
Valley Province, and Kilifi district in Coast Province 
[32], [33] 
Chikungunya virus (Togaviridae) 
Since its detection in 1953 in Tanzania [34], 
Chikungunya virus (CHIKV) has been reported in 
several other regions across the world. CHIKV is a 
single stranded RNA virus belonging to the 
Togaviridae family, Alphavirus genus. It causes a 
febrile illness (Chikungunya fever) characterized by 
sudden onset of high-grade fever and severe chronic 
incapacitating arthralgia [35]. Other possible 
indications are headache, rash, joints swelling and 
muscle pain. There are currently no approved 
vaccines or medications for treatment of the infection 
and breaking of the transmission cycle relies on 
mosquito control.  
CHIKV is transmitted by Aedes mosquitoes (day 
biting mosquitoes) with several outbreaks being 
associated with increased mosquito populations after 
the onset of rainfall [7].This virus is classified into 
three lineages; West-African genotype, 
East/Central/South African genotype and Asian 
genotype based on the nsP4 and E1 gene fragments. 
These phylogenetically diverse groups have been 
seen to occur in the distinct spacio-geographic 
suggested zone with travel-related importations 
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being reported beyond these zones. For instance in 
the case of the Caribbean Island of Saint Martin 
where the first documented autochthonous 
transmission and outbreak in the Americas resulted 
from an imported case of the Asian genotype of 
CHIKV [36].  
Before 2004, several small-scale sporadic outbreaks 
were documented in Democratic republic of Congo 
[37], Malaysia and Indonesia [38]. Significant urban 
outbreaks of Chikungunya were first documented in 
Thailand in the early 1960s  as well as India in 1963-
1973 (39). In 2004, an outbreak in Mombasa and the 
Lamu Island of Kenya resulted in a large-scale 
outbreak which further spread to Comoros Islands, 
Reunion Island, and other Islands on the Indian 
Ocean and eventually to India. This outbreak resulted 
in a 75% infection rate in Lamu Island [40] and an 
approximated 266,000 people infected in the Indian 
Ocean Islands of Reunion and Mauritius [38]. The 
CHKV cycle in Africa has been shown to be 
maintained by the epizootic and sylvatic cycles [41] 
and an urban cycle in Asia [42]. In the 2004-2005 
outbreak, a mutation in the E1 glycoprotein (A226V) 
of the East/Central/South-African genotype was 
evidenced to adapt the CHIKV to the Aedes 
alpopictus consequently increasing transmissibility 
in the Indian Ocean Islands [42].  
In Kenya, a low-level circulation of CHIKV has been 
documented in several serological studies [2], [8], 
[40], [43], [44]. A rapid increase of competent 
vectors is commonly seen in the wet season. In 2016, 
a sporadic outbreak was reported in Mandera County, 
an area with no previous CHIKV reports hence 
expansion to a new geographical area. A 
substantially high Aedes spp. population was 
reported and a possible association with an outbreak 
in neighboring Bula Hawa in Somalia [45]. This 
trend of expansion if not curbed may extend to more 
areas and due to availability of naïve hosts may 
present a devastating case of disease. With no 
available vaccines and antiviral therapy, CHIKV 
deserves attention and a multifaceted approach to 
limit transmission while expanding the existing 
knowledge to develop more specific and targeted 
tools to combat it. 
The 2016 CHIKV outbreak may suffer a challenge in 
capturing the true magnitude of the outbreak due to 
resource- limitation as well as low case reporting. In 
the 2004 outbreak, the Ministry of health reported 
1300 confirmed cases while later studies revealed 
higher infection rates [46]. This underlines the 
significant need to put in place improved methods 
and focused efforts to the control of CHIKV in 
Kenya. 
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Yellow Fever Virus (Flaviviridae) 
Yellow fever virus (YFV) is a mosquito-borne 
flavivirus of major importance in Kenya. Aedes 
aegypti is the primary mosquito vector for YF [47]. 
It is known to be prevalent in tropical regions of 
Africa and Americas. There are five known 
genotypes of YFV namely the Angola, East and 
Central African, West African, East African and the 
South American genotype [48]. YF is estimated to 
have an annual incidence of 200,000 cases with 
30,000 deaths worldwide despite availability of an 
effective vaccine. YF disease-related mortality has 
been associated with individuals who fail to seek 
medical attention with 90% of these occurring in 
Africa [49]. Majority of human cases of the infection 
are known to be asymptomatic whereas symptomatic 
cases are characterized by an onset of fever, 
headache and a mild form undifferentiated febrile 
illness. Severe YF disease has been shown to cause 
high mortality rates of 20%–50% [50], [51] and 
patients present with symptoms such as photophobia, 
myalgias, arthalgias, epigastric pain, anorexia, 
vomiting, jaundice and hemorrhagic fever. The YF-
17D vaccines (17DD and 17D-204) currently in use 
globally are based upon a modified attenuated live 
virus of Asibi strain developed in 1937. Vaccination 
confers lifelong protection. Presently, there is no 
scientific or clinical trial data evidence that indicate 
a specific antiviral or pharmacological therapy being 
effective in treatment of YF; instead, supportive 
clinical management is employed [52], [53]. 
In Kenya, the first reported case of YF was in the 
year 1942 in Kitale, subsequently the second case 
occurred in 1943 in Ngong Road, Langata Forest 
Reserve, the west of Nairobi [54], [55]. In the mid-
1992 to March 1993, a large outbreak caused by the 
East African genotype occurred in the south Kerio 
Valley region, Rift Valley Province resulting in high 
mortality rates. Until the outbreak event, this 
genotype had seemingly disappeared for a period of 
almost 40 years and had yet to be confirmed in a 
clinically apparent outbreak. The main mosquito 
vectors identified during this epidemic were Ae. 
africanus and Ae. keniensis confirming the outbreak 
was a result of a sylvatic cycle [56]. Interestingly, 
despite the rapid urbanization in Kenya, the East 
African genotype has yet to emerge in the urban 
cycle vectored by Ae. (Stegomyia) aegypti [57]. The 
1992/93 outbreak led to the launch of a widespread 
vaccination program in the endemic region, which 
reduced the transmission levels and hence results in 
diminished severity of the outbreak.  
Kenya is not considered a holoendemic country 
although more than half of the country is considered 
an endemic zone for YF transmission (Fig. 1). There 
exists an outward increased risk of YF in Kenya as 
she borders countries like Sudan, Uganda and 
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Ethiopia where YF is endemic or major epidemics 
have occurred. For instance, as recently as 2003, a 
major epidemic occurred in Equatoria Province, in a 
bordering area of Sudan [58]; and in 1966 an 
epidemic occurred in the Gamo Gofa Province of 
Ethiopia near the Kenyan border [59]. All this 
describes why Kenya highly remains in the red-zone 
radar for YF infections. 
 
Figure 1:  YF risk map of Kenya.       Source: WHO 
The most recent notable cases of YF in Kenya were 
reported in March of 2016 in two imported cases. 
The Kenyan nationals, both working in Angola 
presented symptomatic cases, and prior to their travel 
they were not vaccinated for YF [60].  
 Serological case evidence and single case reports 
Several arbovirus serological surveillance programs 
conducted within the country on humans and animal 
hosts indicate that there is an unnoticed widespread 
distribution of arboviruses infections. This section 
discusses the arboviruses that have been identified in 
the conducted serological studies. 
West Nile Virus (Flaviviridae) 
West Nile virus (WNV) is a mosquito-borne virus 
that is classified in the family Flaviviridae, genus 
Flavivirus and closely associated to other viruses like 
Japanese encephalitis, Saint Louis encephalitis, 
Usutu, Kunjin, Kokobera, Stratford, Alfuy and 
Murray Valley encephalitis all belonging to the 
Japanese encephalitis serocomplex [61]. It was first 
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detected in East Africa, first isolated in Uganda’s 
West Nile Province in 1937.  
The geographical distribution of WNV is wide and 
presently known to be in Africa, Europe, Russia, the 
Middle East, India, Australia, North and South 
America and the Caribbean[62]–[65], with recent 
outbreaks also reported in Israel, France, Tuscany 
region in Italy, Greece, South Africa, Hungary, 
southeast Romania and Texas in USA [66]–[70].  
Avian species are important vertebrate amplifying 
hosts and their migratory pattern has greatly 
influenced the re-emergence and global spread of 
WNV [71], [72]. Mosquitoes are infected when they 
suck blood-meal from infected birds. Thereafter, 
they spread the virus on the next susceptible host 
they bite. The primary vectors of WNV are Culex 
pipiens pipiens and Culex pipiens quinquefasciatus 
[73].  
A sero-survey conducted thereafter in the years 1939 
to 1940 showed a widespread human sero-positivity 
in Uganda, Kenya, Democratic Republic of Congo 
and Sudan [74]. In 1950, WNV was isolated for the 
second time in Egypt during a sero-survey that 
demonstrated presence of WNV neutralizing 
antibodies in 70% of participants [75] indicating a 
widespread transmission in the local population. 
West Nile virus is endemic in Kenya and has been 
isolated from mosquitoes [76], [77] and 
ticks (Rhipicephalus pulchellus) [78] in North 
Eastern Kenya.  
There has been no reported case of WNV outbreak in 
Kenya. However, studies have demonstrated its 
presence in field mosquitoes collected from North 
Eastern Province [79], [80] and Turkwell Gorge 
Hydroelectric station in West Pokot, Rift Valley 
Province where vertical transmission was observed 
in Culex univittatus mosquitoes [81]. Other 
implicated potential vectors are C. quinquefasciatus 
and Culex vansomereni. In addition, circulation of 
WNV among wild birds has been confirmed in Tana 
River, Kenya [82]. A sero-epidemiological survey 
involving local communities in Tana River and Ijara 
Kenya indicated that people from irrigated areas 
were 1.27 times more likely to get exposed to WNV 
than those from pastoral areas. A similar survey 
conducted in the local health centers among patients 
that sought treatment for febrile illnesses also 
showed presence of WNV antibodies [83]. 
Although the WNV has been known for a long period 
of time and it still remains a pathogen of public 
health concern in Africa and the world at large, there 
is still no established vaccination or curative regimen 
for it. 
On’yong-nyong Virus (Togaviridae) 
O’nyong-nyong (ONN) virus is an alphavirus within 
the Togaviridae family with three documented 
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genotypes; SG650, Igbo Ora and 37997. It was first 
isolated during a febrile illness outbreak of that 
occurred in 1959/60 affecting the Lake Victoria 
basin in Uganda and Kenya and extending to 
Tanzania (82). This was an extensive outbreak with 
over 2,000,000 individuals infected. The infection is 
characterized by fever, severe joint pain, rash as well 
as generalized lymphadenopathy. The symptoms are 
quite similar to those caused by Chikungunya and 
Dengue viruses. There are no vaccines or antiviral 
drugs for ONNV and control is dependent on vector 
management. Anopheles gambiae complex and 
Anopheles funestus are the major vectors for the 
transmission of ONNV. These mosquitoes are 
prevalent in the tropics of Africa and dwell in close 
association with humans increasing chances of 
transmission.  
In 1996/97, after 35 years of seeming disappearance, 
the disease emerged in the Southern areas Uganda 
[85]. The infecting strain was shown to be of the 
SG650 strain closely related to the Igbo Ora strain of 
ONNV and CHIKV [86]. In 1978, ONNV was also 
isolated from a sample of pooled Anopheles 
mosquitoes during a non-epidemic period [87]. 
These studies showed a presence of ONNV in East 
Africa in the periods leading up to the epidemic of 
1996/97 in Uganda. Several serological studies 
investigating the status of arboviral diseases in the 
inter-epidemic periods in Kenya have shown an 
ongoing low-level transmission and therefore 
probably smaller undocumented infections 
especially in the coastal regions [9], [43], [88]. 
ONNV was previously believed to be restricted to the 
African continent but in 2013 it was imported to 
Europe, Germany by a tourist from East Africa and 
it was documented that she acquired the infection in 
the Kenyan Lake region [89]. This importation did 
not cause further transmissions perhaps due to the 
absence of the competent Anopheline vectors in 
Europe. It has been suggested that the Aedes 
mosquito may be a competent vector for ONNV [90], 
however this requires further investigation. Aedes 
mosquito species are more widely distributed and 
adapted in other continents apart from Africa, and 
their potential ability to transmit this virus is a 
serious concern for the global public health.  
Crimean Congo Hemorrhagic Fever Virus 
(Nairoviridae) 
Crimean-Congo hemorrhagic fever virus (CCHFV) 
is a severe tick-borne hemorrhagic fever virus that 
belongs to the family Nairoviridae. It is the causative 
agent for Crimean-Congo hemorrhagic fever. 
CCHFV was foremost described as a clinical entity 
in 1944–45 in soviet military soldiers in Cremia just 
before World War II [91]. Thereafter, Crimean 
haemorrhagic fever virus was proven to be 
antigenically indistinguishable from Congo virus, 
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which had been isolated from a febrile patient in 
Belgian Congo [Democratic Republic of the Congo] 
in 1956 (90) hence its current name. 
CCHF disease has a wide global distribution ranging 
from eastern Europe and the Crimea, to the Middle 
East and western China, Pakistan, and Africa. This 
correlates the distribution of Hyalomma ticks; the 
principle viral transmission vectors to humans [93]–
[96]. 
CCHF is a fatal disease with its clinical manifestation 
varying from a subclinical disease to a multiple organ 
failure and shock case. Naturally, its symptoms 
include high fever, headache, malaise, arthralgias, 
nausea, myalgias, abdominal pain, and in rare cases 
diarrhea [97], [98]. 
Prior to the year 2000, CCHFV had been detected 
only once in 1970s in Rhipicephalus pulchellus ticks 
which were obtained from a dying sheep in a 
veterinary laboratory in Kabete town, near Nairobi 
[99]. Then the first documented case of human 
infection with CCHFV infection in Kenya was made 
on October 21, 2000 from 25-year-old male farmer 
who was admitted to a mission hospital in western 
Kenya with an acute hemorrhagic illness: this was 
later confirmed to be CCHF [100].  
Ongoing arbovirus surveillance systems through 
screening of Hyalomma spp ticks from livestock 
have shown evidence of CCHFV circulation in North 
Eastern Kenya hence indicating a possible human 
exposure [101]. 
In 2010-2011 period, a seroprevalence study done in 
North-Eastern province showed a rate of 23% in 
Sangailu and 14% in Ijara region and the most 
exposed persons were of age 40–49 years and 
farmers had a 29% probability of exposure compared 
to other occupations. Also, this study identified age, 
location and contact to donkeys as significant risk 
factors associated with CCHV exposure [102]. 
Previous evidence for C-CHFV in Kenya is limited 
and based on serology (human and bovine) and two 
isolations of C-CHFV from non-human sources.  
Other Arboviruses reported in Kenya 
Metagenomic and other studies of arthropod vectors 
as well as the human population in Kenya have 
shown quite a notable prevalence of arboviral agents 
in circulation. In mosquitoes and ticks viruses such 
as Ndumu virus, Sindbis virus, Bunyamwera virus, 
Pongola virus, Usutu virus, Ngari virus, Babanki 
virus, Chaoyang-like virus, Quang Binh-like virus, 
Wesselsbron virus, Middelburg virus, Bhanja virus, 
Dugbe virus, Hazara virus, Middelburg virus, 
Semiliki Forest virus, Thogoto Virus, Dhori virus, 
Kadam virus, Barur virus as well as Foot-and-Mouth 
disease virus [3], [88], [103] have been reported. 
Some of these viruses have been associated with 
human disease, such as Babanki virus (Central 
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African Republic), Bunyamwera virus (several 
African countries), Sindbis virus (Uganda, South 
Africa and Australia), Pongola virus (Uganda), 
Usutu virus (Africa and Italy), Ngari virus (Africa 
including Kenya), Semiliki Forest Virus (Africa and 
Asia), Bhanja virus (USA and Europe), Dugbe virus 
(Africa), Thogoto virus(Africa including Kenya), 
Kadam virus (Uganda),Dhori (India), Wesselsbron 
(Afica) and Middelsburg (Africa). Some of the above 
viruses have been isolated from patients presenting 
with febrile illness or encephalitis while antibodies 
against others have been detected by neutralization 
assays in patient sera (102). In Kenya, fevers of 
unknown origin (FUO) are severally treated as 
malaria owing to limitations in diagnostic techniques. 
There is need to develop and provide kits and 
systems for arbovirus diagnostics for the healthcare 
system. These viruses are most likely circulating in 
the population undetected and have a large potential 
to lead to outbreaks in the future. This is a recipe for 
mismanagement and hence disaster in the case where 
outbreaks meet unpreparedness. 
Overall arboviruses risk assessment in Kenya 
Many arbovirus diseases are uncontrolled and the 
involved causative viruses are not only a unique issue 
to Kenya, but also form a larger part of the global 
issue on emerging and reemerging pathogens that 
can cause serious human diseases. Arboviruses have 
a vast choice of arthropod vectors that are capable of 
being infected and in turn transmitting the disease. 
Mosquitoes, ticks, midges, sandflies and bugs are the 
major arthropods that are involved in transmission 
cycle of the arboviruses [105] although the most 
predominant ones are mosquitoes and ticks. More 
than 300 species of mosquitoes can transmit 
arboviruses. Aedes spp and Culex spp mosquitoes are 
able to transmit more than 100 types of arboviruses 
[104]. In Kenya, rich abundance of competent 
arbovirus vectors has been determined in various 
studies hence leading to high arbovirus transmission 
risks [80], [106]–[108]. Typical tropical climate 
features such as rainfall, wind, temperature and 
humidity have been described to influence the 
growth and thriving of arbovirus vectors [109]. 
Kenya lies squarely in the tropical region and some 
of these factors may be playing a major role in the 
evident thriving of these vectors and at large the 
transmission cycle of arboviruses. Limited capacity/ 
preparedness of Kenyan public health systems in 
detection and diagnosing of a variety of infections 
are also a major key issue in the fight against 
arboviruses. Clinical hospitals rely mostly on 
symptomatic case analysis which may lead to disease 
misdiagnosis. Therefore, the potential risk of the 
arboviruses, arboviral diseases and their transmitting 
vectors should be carefully evaluated and immediate 
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approaches to mitigate the risks should be developed 
and implemented.  
Conclusion 
Serological studies have shown that Arboviruses 
continue to circulate in the inter-epidemic periods in 
Kenya. Several cases of infections go undetected due 
to cases of misdiagnosis or under-reporting and 
eventually go undocumented hence the arbovirus 
burden in Kenya is very likely higher than the current 
estimates as a number of site-limited studies have 
confirmed. To effectively reduce and henceforth 
combat the arboviral risk in Kenya, there is urgent 
and solemn need to; [1] Implement rigorous control 
strategies of arboviral vectors guided by accurate 
diagnostics in the both epidemic and inter-epidemic 
periods, especially in regions where outbreaks have 
occurred in the past. The various, already proven 
vector-control strategies, can include the application 
of biolarvicides that utilize application of certain 
strains of Bacillus sphaericus and Bacillus 
thuringiensis that produce very effective 
mosquitocidal toxins even at low doses against 
mosquito larvae and are deemed safe to other non-
target organisms [110]–[112] together with the most 
recent novel strategies involving the development of 
transgenic mosquitoes that harbor dominant toxic 
genes, the introduction of arbovirus-blocking 
microorganisms into mosquitoes, and the 
development of  acquisition-and-transmission-
blocking therapeutics [113]; [2] Invest in efficient 
modern day diagnostic test methods and tools that 
have a high specificity and sensitivity to arboviruses. 
This is a critical part of determining and 
differentiating arboviral infections as their clinical 
presentations are often non-specific. The currently 
applied tools have the limitation of cross-reactivity 
especially for flaviviruses, impacting reliability of 
the results obtained; [3] Countrywide surveillance 
studies should be undertaken to obtain a clear 
outlook of the true burden of arboviral disease. 
Characterization of the circulating viruses will 
provide key knowledge on the viruses’ genome, 
evolution and adaptations may provide insight for 
vaccine or drug development. Also, vector control 
strategies should be a priority put in place especially 
in outbreak hotspots as outlined by already gathered 
surveillance data. 
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INFORGRAPHICS - ARBOVIRUS CASES 
 
Figure 2: A timeline showing Arbovirus outbreaks and reported cases since 1912 to 2016. Each color represents one virus type. 
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